BioCentury | Oct 22, 2020
Politics, Policy & Law

Protecting biomedical innovation as a national security asset: Guest Commentary

...he has been a senior executive of Cephalon Inc....
BioCentury | Aug 10, 2018
Company News

FDA reviewers say data are lacking on TIRF drug use

...most subscribed in 2017. In the U.S., Insys Therapeutics Inc. (NASDAQ:INSY) markets Subsys, and the Cephalon Inc....
BioCentury | Jan 19, 2018
Clinical News

FDA approves Teva's Trisenox for newly diagnosed APL

...from Teva under a 2005 deal in which Cephalon Inc. acquired Trisenox from CTI. Teva acquired Cephalon...
BioCentury | Jun 20, 2016
Company News

Mesoblast, Teva deal

...Phase III testing to treat congestive heart failure (CHF). Under a 2010 deal, Mesoblast and Cephalon Inc....
BioCentury | Jun 11, 2016
Company News

Eagle soars after bendamustine patent ruling

...District Court for the District of Delaware upheld most claims of a patent from the Cephalon Inc....
BioCentury | Mar 24, 2016
Company News

FDA approves Teva's Cinqair for asthma

...Cinqair, which is under review in the EU and Canada, via its 2011 acquisition of Cephalon Inc....
BioCentury | Dec 10, 2015
Company News

FDA panel backs Teva's reslizumab for adults

...IL-5 (see BioCentury Extra, Nov. 4) . Teva acquired reslizumab via its 2011 acquisition of Cephalon Inc....
BioCentury | Sep 19, 2015
Company News

FDA committee to discuss Teva's asthma biologic

...the humanized mAb against IL-5, formerly known as Cinquil , through its 2011 acquisition of Cephalon...
BioCentury | Jul 27, 2015
Company News

AstraZeneca, Biogen, Teva pharmaceuticals news

...companies defrauded the government by under-reporting Medicare rebates. Specifically, AstraZeneca will pay $46.5 million, Teva’s Cephalon Inc....
BioCentury | Jun 22, 2015
Clinical News

Reslizumab regulatory update

...in March 2016. Teva gained the humanized mAb against IL-5 through its 2011 acquisition of Cephalon Inc....
Items per page:
1 - 10 of 1540
BioCentury | Oct 22, 2020
Politics, Policy & Law

Protecting biomedical innovation as a national security asset: Guest Commentary

...he has been a senior executive of Cephalon Inc....
BioCentury | Aug 10, 2018
Company News

FDA reviewers say data are lacking on TIRF drug use

...most subscribed in 2017. In the U.S., Insys Therapeutics Inc. (NASDAQ:INSY) markets Subsys, and the Cephalon Inc....
BioCentury | Jan 19, 2018
Clinical News

FDA approves Teva's Trisenox for newly diagnosed APL

...from Teva under a 2005 deal in which Cephalon Inc. acquired Trisenox from CTI. Teva acquired Cephalon...
BioCentury | Jun 20, 2016
Company News

Mesoblast, Teva deal

...Phase III testing to treat congestive heart failure (CHF). Under a 2010 deal, Mesoblast and Cephalon Inc....
BioCentury | Jun 11, 2016
Company News

Eagle soars after bendamustine patent ruling

...District Court for the District of Delaware upheld most claims of a patent from the Cephalon Inc....
BioCentury | Mar 24, 2016
Company News

FDA approves Teva's Cinqair for asthma

...Cinqair, which is under review in the EU and Canada, via its 2011 acquisition of Cephalon Inc....
BioCentury | Dec 10, 2015
Company News

FDA panel backs Teva's reslizumab for adults

...IL-5 (see BioCentury Extra, Nov. 4) . Teva acquired reslizumab via its 2011 acquisition of Cephalon Inc....
BioCentury | Sep 19, 2015
Company News

FDA committee to discuss Teva's asthma biologic

...the humanized mAb against IL-5, formerly known as Cinquil , through its 2011 acquisition of Cephalon...
BioCentury | Jul 27, 2015
Company News

AstraZeneca, Biogen, Teva pharmaceuticals news

...companies defrauded the government by under-reporting Medicare rebates. Specifically, AstraZeneca will pay $46.5 million, Teva’s Cephalon Inc....
BioCentury | Jun 22, 2015
Clinical News

Reslizumab regulatory update

...in March 2016. Teva gained the humanized mAb against IL-5 through its 2011 acquisition of Cephalon Inc....
Items per page:
1 - 10 of 1540